A carregar...
Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient
Drive gene mutation positive non‐small cell lung cancer achieves reliable clinical responses to subsequent target therapy. However, most patients will inevitably develop disease progression with multiple treatment failure. Next generation sequencing can identify clear resistance mechanisms. We repor...
Na minha lista:
| Publicado no: | Thorac Cancer |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons Australia, Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6501016/ https://ncbi.nlm.nih.gov/pubmed/30788907 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13015 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|